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https://doi.org/10.1016/j.ccell.2019.03.005SUMMARYThe BCR-ABL1 fusion protein is the cause of chronic myeloid leukemia (CML) and of a significant fraction of
adult-onset B cell acute lymphoblastic leukemia (B-ALL) cases. Using mouse models and patient-derived
samples, we identified an essential role for g-catenin in the initiation and maintenance of BCR-ABL1+
B-ALL but not CML. The selectivity was explained by a partial g-catenin dependence of MYC expression
together with the susceptibility of B-ALL, but not CML, to reduced MYC levels. MYC and g-catenin enabled
B-ALL maintenance by augmenting BIRC5 and enforced BIRC5 expression overcame g-catenin loss. Since
g-catenin was dispensable for normal hematopoiesis, these lineage- and disease-specific features of canon-
ical Wnt signaling identified a potential therapeutic target for the treatment of BCR-ABL1+ B-ALL.INTRODUCTION
The Philadelphia chromosome (Ph), which encodes the BCR-
ABL1 fusion protein, is the cause of chronic myeloid leukemia
(CML) and of 30% of adult-onset B cell acute lymphoblastic leu-
kemia (B-ALL) cases. Small-molecule tyrosine kinase inhibitors
of the constitutively active BCR-ABL1 can effectively control
chronic phase CML, but are not curative. Moreover, a significant
fraction of CML patients responds poorly to tyrosine kinase in-
hibitor treatment due to mutations in BCR-ABL1. Even worse,
Ph+ B-ALL patients only transiently respond to inhibitor treat-Significance
Philadelphia chromosome-positive (Ph+) (BCR-ABL1+) B cell a
after combined treatment with tyrosine kinase inhibitors and
additional therapeutic targets. We have identified g-catenin a
BCR-ABL1, which maintained Ph+ B-ALL by sustaining the
BIRC5 (Survivin). Since targeting g-catenin overcame the resis
enin expression was not essential for steady-state hematopo
which may circumvent the likely side effects of a global inhibiment and have a poor prognosis (Hunger, 2011; O’Hare et al.,
2012). Thus additional therapeutic targets are needed to control
and eventually cure Ph+ leukemia.
Mouse models revealed that CML originates from long-term
hematopoietic stem cells (LT-HSC) and is propagated by LT-
HSC-like leukemia-initiating cells (LIC) (Huntly et al., 2004),
which are resistant to inhibitor treatment (Hu et al., 2006). Thus
BCR-ABL1 exploits the self-renewal capacity of LT-HSC for
the sustained overproduction of mature myeloid cells. In
contrast, the cancer-propagating cell for B-ALL resembles pro-
B cells (Signer et al., 2010), and multiple developmental stagescute lymphoblastic leukemia (B-ALL) has a high relapse rate
chemotherapy, highlighting a need for the identification of
s a key component of a signaling cascade downstream of
expression of the critical downstream targets MYC and
tance of Ph+ B-ALL cells to ABL kinase inhibitors and g-cat-
iesis, our findings identified a potential therapeutic target,
tion of the canonical Wnt pathway.
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can serve as a cell of origin for B-ALL, including LT-HSC, com-
mon lymphoid progenitors, and lineage-restricted pro-B cells
(Kovacic et al., 2012; Signer et al., 2010). The BCR-ABL1
mediated self-renewal of lineage-committed B cells is poorly
understood.
Self-renewal and differentiation of hematopoietic stem and
progenitor cells is associated with canonical Wnt signals. Aber-
rantly increased expression of Wnt pathway components is
observed in various types of leukemia (Jamieson et al., 2004;
Lu et al., 2004) and abnormal Wnt/b-catenin signaling has a crit-
ical role in multiple myeloma (Yeung et al., 2010), acute myeloid
leukemia (AML) (Wang et al., 2010), and CML (Hu et al., 2009;
Schurch et al., 2012; Zhao et al., 2007). Indeed, b-catenin (en-
coded by Ctnnb1) plays an essential role for the generation
(Zhao et al., 2007) and the maintenance of CML LIC (Heidel
et al., 2012) and their resistance to tyrosine kinase inhibitors
(Hu et al., 2009). While b-catenin-deficiency largely prevented
the induction of CML by BCR-ABL1, recipient mice instead suc-
cumbed to B-ALL (Zhao et al., 2007). BCR-ABL1+ lymphocytic
leukemia may thus not depend on the Wnt pathway or depend
on the alternative Wnt signal transducer g-catenin (Junction
plakoglobin, encoded by JUP). Consistent with a possible role
in leukemia, g-catenin expression is frequently upregulated in
AML (Morgan et al., 2012; Muller-Tidow et al., 2004; Zheng
et al., 2004), and enforced expression of g-catenin in hematopoi-
etic progenitors induced a myeloproliferative syndrome (Zheng
et al., 2004). However, it has not been known whether g-catenin
is essential for leukemia initiation or maintenance and, if so,
whether there exist lineage-specific roles for g-catenin and/or
b-catenin.
RESULTS
g-Catenin Is Essential for Initiating Ph+ B-ALL
To investigatewhetherg-catenin playeda role forB-ALLdevelop-
ment, we used bone marrow (BM) from g-catenin-deficient
(Jup/) and wild-type (WT, Jup+/+) fetal liver chimeras (CD45.2)
(Figure S1A). Infection of total BM cells with a retrovirus encoding
BCR-ABL1 (p210) andGFP lead to thepreferential transduction of
B220+ cells (Figure S1B). Following transplantation into irradiated
C57BL/6 (B6)mice (CD45.1),most recipients receiving Jup+/+ BM
(90%) developed B-ALL (Figures 1A and 1B), which was charac-
terized by frequent hind leg paralysis, moderate splenomegaly,
pleural effusion, enlarged lymph nodes (Figure 1C), and expan-
sions of cells with a pre-B cell phenotype (B220+CD43dimCD19+
BP-1+IgM) in the BM, secondary lymphoid organs, and blood
of recipients (Figure 1D and data not shown) (RoumiantsevFigure 1. Impaired B-ALL Initiation in the Absence of g-Catenin
(A–D) Wild-type (WT) recipients (CD45.1) were transplanted with BCR-ABL1 (p2
recipient mice were analyzed for survival (compiled from four independent exper
presence of donor-derived (CD45.2+) GFP+ (BCR-ABL1+) B220+ CD11b B cells
(E and F) GFP+ (BCR-ABL1+) cells were analyzed 2–3 weeks post transplantatio
(G) Disease-free recipients of Jup/ BM were analyzed >8 weeks after trans
compared with recipients of Jup+/+ BM with B-ALL disease.
(H and I) BCR-ABL1+ (mCherry+) B220+ BP-1+ cells were analyzed 2–3 weeks po
(J) BM cells from Juplox/lox Vav-Cre (JupD/D) and Juplox/lox (Jup+/+) mice were cultu
Primary colonies, all consisting only of B-lineage cells, were harvested and replate
and tertiary plating) and are representative of two independent experiments.
Error bars in (E) and (G) to (J) represent SD. *p < 0.05, **p<0.01, ***p < 0.001. nset al., 2001). The remaining recipients (10%) showed mixed
B-ALL/myeloid expansions, with symptoms characteristic of
B-ALL rather than CML-like disease (see later). In contrast, a sig-
nificant fraction (41%) of recipients of BCR-ABL1 transduced
Jup/ BM did not develop disease for >80 days (Figures 1A
and 1B). While a few of the remaining recipients developed
B-ALL (9%), some showed a mixed B-ALL/myeloid phenotype
(14%) and a larger fraction succumbed to CML-like disease
(36%) (Figure 1B). Thus, B-ALL initiation byBCR-ABL1 depended
on g-catenin.
Impaired initiation of Ph+ B-ALL was not related to evident
perturbations of normal hematopoiesis (Figure S1C) or B cell
development in Jup/ chimeras (Figure S1D). Furthermore,
Jup+/+ and Jup/ BM cells were transduced with comparable
efficiency (Figure S1E). Between 2 and 3 weeks after transplan-
tation of transduced BM, but prior to the development of overt
signs of leukemia (referred to as pre-leukemic stage), we noted
comparable populations of BCR-ABL1+ B cells in the BM and
spleen of recipient mice although Jup/ B cells were reduced
in the blood (Figure 1E). BCR-ABL1+ cells had an identical
phenotype (B220+CD43dimBP-1+IgM) and expressed compa-
rable amounts of BCR-ABL1 protein (Figure 1F). Despite the
efficient initial engraftment and expansion, disease-free recipi-
ents of Jup/ BM (41%) contained few BCR-ABL1+ pre-B cells
8 weeks after transplantation (Figure 1G), indicating that g-cat-
enin sustained the expansion of BCR-ABL1+ B cells. Consistent
with this observation, BCR-ABL1+ Jup/ pre-B cells were
more susceptible to undergo apoptosis and proliferation was
modestly reduced compared with WT (Figures 1H and 1I). We
further estimated cancer cell self-renewal in vitro using serial
replating assays. Following primary plating, both WT and
JupLox/Lox Vav-Cre (JupD/D) BCR-ABL1+ BM cells readily formed
B cell colonies. While WT B cells efficiently formed colonies in
subsequent platings, that of JupD/D cells was progressively
reduced (Figure 1J). In all cases colonies were composed of
B-lineage cells (data not shown). Thus the transient expansion
and impaired progression to B cell leukemia could be accounted
for by an impaired proliferative renewal in the absence of
g-catenin.
Transformation of B-Lineage-Committed Progenitors
Depends on g-Catenin Expression
CML arises from HSC expressing BCR-ABL1, but not from
more differentiated myeloid progenitors (Huntly et al., 2004).
In contrast, B-ALL can arise from B cell lineage-committed
progenitors (Kovacic et al., 2012; Signer et al., 2010). In agree-
ment with these findings, BCR-ABL1 transduced purified WT10) (GFP) transduced BM cells from Jup+/+ or Jup/ chimeras (CD45.2) and
iments) (A), leukemia type (B), appearance of spleen and lymph nodes (C), and
in the recipient BM (D).
n for their abundance (E) and the expression of BCR-ABL1 (F).
plantation for the presence of residual GFP+ (BCR-ABL1+) B220+ B cells as
st transplantation for markers of cell death (H) and cell-cycle progression (I).
red in IL-7 or transduced with BCR-ABL1 (p185) and plated in methylcellulose.
d. Data are mean number of colonies derived from 104 B-ALL cells (secondary
, not significant (p > 0.05). See also Figure S1.
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Figure 2. g-Catenin Maintains Established Ph+ B-ALL
(A and B)WT recipients (CD45.1) were transplanted with purified B220+ CD19+ IgM pro-B and pre-B cells transduced with BCR-ABL1 (p210), and recipient mice
were analyzed for survival (compiled from two independent experiments) (A) and disease type (B).
(C and D) WT recipients (CD45.1) were transplanted with BCR-ABL1 (p185) (GFP) transduced BM cells from Juplox/lox Mx1-Cre or Juplox/lox mice (CD45.2), and
recipient mice were analyzed for the presence of BCR-ABL1+ B cells in the BM 7 days later (C) and for survival following the injection of poly(I:C) pIC to delete Jup
(D). Data are from n = 9–12 mice per group, compiled from two independent experiments.
(legend continued on next page)
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B220+CD19+IgM pro-B and pre-B cells readily induced B-ALL
in recipient mice (8/8 recipients) (Figures 2A and 2B). These
B-ALL cells were fully transformed, as they gave rise to leukemia
in secondary recipients (data not shown). In contrast, Jup/
pro-B and pre-B cells completely failed to induce B-ALL (0/8
recipients) (Figures 2A and 2B). The death of two of the recipi-
ents (pink dots) was not associated with an expansion of BCR-
ABL1+ cells. Indeed, immature B cells expressed Jup mRNA
(Figure S2A). Thus initiation of BCR-ABL1+ B-ALL in B-lineage-
committed progenitor cells depended on g-catenin.
Continuous g-Catenin Expression Is Needed toMaintain
Established Ph+ B-ALL
We further addressed whether continuous g-catenin expression
was necessary to propagate B-ALL disease. To this endwe com-
bined a conditional Jup allele (Juplox/lox) with inducible Cre
expression. BM cells from Juplox/lox Mx1-Cre mice were trans-
duced with BCR-ABL1 (p185) before transplantation into recip-
ient mice. Transduced B220+ cells were readily detected in the
BM and blood of recipient mice 7 days later (Figure 2C and
data not shown) when Cre expression was induced (using
poly(I:C) [pIC] administration) to delete Jup. While recipients
injected with pIC remained symptom free for >60 days (Fig-
ure 2D) and showed no evidence of residual disease upon sacri-
fice (Figure S2B), untreated recipients essentially all succumbed
to B-ALL disease within 20–40 days post transplantation (Fig-
ure 2D). Recipients of Juplox/loxBM (lackingMx1-Cre) succumbed
to B-ALL independent of pIC administration. Thus, continuous
g-catenin expression was essential to maintain B-ALL disease.
g-Catenin and b-Catenin Play Selective Roles for B-ALL
and CML, Respectively
We next determined whether g-catenin also played a role for the
development of CML-like disease. Since CML originates from
HSC, we transduced purified Lin Sca1+ c-Kit+ (LSK) cells
from Juplox/lox and Juplox/lox Vav-Cre (JupD/D) mice with BCR-
ABL1 (p210) (Figure S2C). All recipients of control and JupD/D
LSK cells developed CML-like disease (Figures 2E and S2D),
which was characterized by weight loss, splenomegaly, pulmo-
nary hemorrhage, and aberrant expansion of CD11b+ GR1+
granulocytes in the BM, spleen, and blood (Figures 2F and 2G;
and data not shown). CML initiation was also comparable using
BM progenitors from 5-fluorouracil-treated Jup+/+ and Jup/
fetal liver chimeras (data not shown). Thus, g-catenin was
dispensable for CML but essential for the induction and mainte-
nance of B-ALL.
Our findings together with published data (Hu et al., 2009;
Zhao et al., 2007) raised the question of whether g-catenin and
b-catenin played selective roles in B-ALL and CML, respectively.
While CML did not develop in the absence of b-catenin (Hu et al.,
2009; Zhao et al., 2007), the majority of recipients of Ctnnb1/(E–G) WT recipients (CD45.1) were transplanted with BCR-ABL1 (p210) transd
Juplox/loxmice, and recipient mice were analyzed for survival (E), the appearance o
(BCR-ABL1+) CD11b+ Gr-1+ granulocytes (G).
(H and I) WT recipients (CD45.1) were transplanted with BCR-ABL1 (p210) transd
recipient mice were analyzed for survival (compiled from three independent exper
type (I).
See also Figures S2 and S3.HSC eventually succumbed to B-ALL (Zhao et al., 2007), sug-
gesting that b-catenin was not required for B-ALL initiation. How-
ever, since recipients of WT HSC developed CML, it was
possible that b-catenin suppressed B-ALL initiation. Transduc-
tion of WT (Ctnnb1lox/lox or Vav-Cre transgenic) or Ctnnb1lox/lox
Vav-cre (Ctnnb1D/D) BM with BCR-ABL1 (p210) resulted in com-
parable B-ALL induction (8/9, 89% for WT and 8/11, 73% for
Ctnnb1D/D) (Figures S2E and S2F). PCR analyses confirmed
Ctnnb1 deletion in these B-ALL samples (Figure S2G). Thus
b-catenin had no major role in Ph+ B-ALL initiation, suggesting
that g-catenin and b-catenin played selective roles in B-ALL
and CML, respectively.
We further addressed whether g-catenin signaling played a
role for B-ALL initiation. g-Catenin can associate with Tcf/Lef
transcription factors and transduce canonical Wnt signals (Jean-
net et al., 2010). Lef1 was the most highly expressed Tcf/Lef
family member in normal (data not shown) and Ph+ B cells in
pre-leukemic mice (Figure S3A). To address a role of Lef1, we
used fetal liver cells from Lef1+/+ and Lef1/ embryos (Fig-
ure S3B), which had a comparable compartment of B220+ B cells
(Figure S3C), except that Lef1/ B220+ cells lacked BP-1 (data
not shown) as noted before (Reya et al., 2000). Three weeks post
transplantation of BCR-ABL1 (p210) transduced fetal liver cells,
recipients of Lef1+/+ and Lef1/ BM contained comparable
populations of BCR-ABL1+ B cells in the blood (Figure S3D), indi-
cating equivalent engraftment and initial expansion of Ph+ cells.
However, while Lef1+/+ fetal liver yielded B-ALL in the majority of
recipients (9/13; 69%), fewer recipients of Lef1/ fetal liver
developed B-ALL (3/9; 33%) (Figures 2H and 2I). In contrast to
Lef1, Tcf1 (encoded by the Tcf7 gene) did not alter B-ALL induc-
tion (Figures S3E and S3F). Thus, Lef1 played a significant
role for the induction of Ph+ B-ALL, consistent with the idea
that g-catenin acted at least in part via Lef1, and thus in the
context of the canonical Wnt signaling pathway.
g-Catenin Expression Maintains Human Ph+ B-ALL
We next addressed whether g-catenin was essential for human
Ph+ B-ALL. Similar to murine Ph+ B-ALL (Figure 3A), g-catenin
protein was readily detected in six human Ph+ cell lines (Sup-
B15, K562, BV-173, TOM-1, SD-1, and NALM-1) (Figure 3B)
and inpatient-derivedB-ALLsamples (Figure 3C) as notedbefore
(Gang et al., 2014). Knockdown of g-catenin increased the
apoptosis and suppressed the expansion of all six Ph+ cell lines
(Figures 3D, 3E, 3F, S4A, and S4B). Thus, several Ph+ cell lines,
which are resistant to the tyrosine kinase inhibitor imatinib (Sup-
B15, SD-1, and NALM-1) (see later), depended on g-catenin.
g-Catenin knockdown also impaired the expansion of Sup-
B15 cells transplanted into immunodeficient NOD Prkdcscid
Il2rg/ (NSG) mice (Figure 3G). Furthermore, patient-derived
Ph+ B-ALL cells were transduced with Sh JUP or Sh scr
constructs co-expressing fluorescent proteins, which had beenuced with Lin Sca-1+ c-kit+ (LSK) cells from Juplox/lox Vav-Cre (JupD/D) and
f the spleen and the lung (F), and the presence of donor-derived (CD45.2+) GFP+
uced with fetal liver cells from E14 Lef1+/+ and Lef1/ embryos (CD45.2), and
iments using n = 5–6 independent donor embryos of each type) (H) and disease
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Figure 3. g-Catenin Maintains Human Ph+ B-ALL
(A–C) Expression of g-catenin in murine BCR-ABL1+ (p185) B cells from replating assays or primary B-ALL (A), human Ph+ cell lines (B), or patient-derived Ph+
B-ALL samples (huCD19+) (C).
(D–G) Sup-B15 cells stably expressing short hairpins (Sh) to g-catenin (Sh JUP1 or Sh JUP2) or a scrambled control hairpin (Sh scr) were analyzed for the
expression of g-catenin andMYC (D), apoptosis (E), cellular expansion in vitro (mean number of live cells over time as comparedwith input) (F), or the expansion in
NSG mice (G). The scatterplot shows the number of human cells (human b2m+) in the BM of NSG mice. All data are representative of two or more independent
experiments.
(H–J) Ph+ B-ALL cells from patient #1 transduced with control Sh scr (GFP) and Sh JUP2 (co-expressing the cyan fluorescent protein Cerulean) constructs were
analyzed for the transduction efficiency in vitro (input) (H) or transplanted into NSG mice and analyzed for the presence of human (hu) CD19+ cells expressing Sh
scr (GFP+) or Sh JUP2 (Cerulean+) in the blood of recipient mice 6 weeks later (I) whereby the frequencies of transduced huCD19+ cells in recipient mice were
compared with input (J). Representative of two experiments each with n = 3–4 mice per group.
Data in (F) and (J) are means ± SD; the horizontal bar in (G) depicts the mean. **p < 0.01. See also Figure S4.validated in K562 cells (Figure S4C). Transduced cells were
mixed in equal proportions and maintained in vitro for 2–6 days
to verify the input (Figures 3H and S4D) or were transplanted
into NSG mice. Cells expressing the control Sh scr construct
(GFP+) represented a stable fraction of patient-derived B-ALL654 Cancer Cell 35, 649–663, April 15, 2019cells in vivo, and that fraction corresponded to the input. In
contrast, relative to input, Sh JUP2-expressing cells (Cerulean+)
had almost completely disappeared from peripheral blood, the
spleen, and the BM of NSG mice (Figures 3I and 3J). Corre-
sponding data were obtained using B-ALL cells from a second
A B
C D FE
G H I
J
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Figure 4. A Normal Myc Gene Dosage Is Essential to Maintain Established Ph+ B-ALL
(A) Expression of the indicated Wnt target and/or pathway genes in Jup+/+ and Jup/ pre-leukemic Ph+ B cells.
(B–D) Expression of Myc in pre-leukemic Ph+ B cells compared with the corresponding and the subsequent normal stages of B cell developmental (B), in
pre-leukemic Ctnnb1lox/lox and Ctnnb1D/D Ph+ B cells (C), and in normal BP-1+ pre-B cells from MycD/+ as compared with Myc+/+ mice (D).
(E–H) WT recipients (CD45.1) transplanted with BCR-ABL1 (p210) transducedMyc+/+ orMycD/+ BMwere analyzed for survival (compiled from three independent
experiments using n = 4–6 donors of each type) (E), disease type (F), the presence of CD45.2+ BCR-ABL1+ (mCherry+) Ph+ B cells in the blood of pre-leukemic
mice (G), and Myc expression in pre-leukemic B cells (H).
(legend continued on next page)
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patient (Figures S4D and S4E). Loss of patient-derived Ph+
B-ALL cells was confirmed using a Sh JUP1 (GFP) construct
versus a Sh scr [Cerulean] control (data not shown). The latter
also ensured that cell loss was independent of the color combi-
nation. Collectively these data demonstrated that the mainte-
nance of patient-derived Ph+ B-ALL in xenografts depended
on g-catenin expression.
In addition to Ph+ B-ALL, g-catenin was expressed in a small
set of B-ALL cell lines with distinct translocation products (Fig-
ure S4F), and the expansion of these cells also depended on
g-catenin (Figure S4G), although some of these B-ALL subtypes
may also depend on b-catenin (Gang et al., 2014). Indeed JUP
was upregulated in clinical B-ALL samples irrespective of the
t(9; 22) translocation. Moreover, JUP was also overexpressed
in certain AML subtypes, in agreement with previous studies
(Morgan et al., 2012; Muller-Tidow et al., 2004; Zheng et al.,
2004), but not in CML, T-ALL, or CLL (Figure S4H). In contrast,
CTNNB1 expression did not vary among hematological malig-
nancies (Figure S4I), indicating that g-catenin may play a role
in additional hematological malignancies.
A Critical Role of the Myc Gene Dosage in the
Maintenance of Ph+ B-ALL
To identify g-catenin target genes, we conducted a gene expres-
sion analysis of flow sorted BCR-ABL1+ B220+ BP-1+ cells from
the BM of pre-leukemic mice. This analysis identified 91 genes
that were differentially expressed (adjusted p value <0.1),
whereby 40 genes were upregulated and 51 were downregu-
lated (shown in part in Table S1). Pathway analysis using
GeneGO revealed an increase of ‘‘transcription regulation of
granulocyte development’’ in the absence of g-catenin (Mpo,
Elane, and Prtn3, p = 0.0004). Furthermore, the top three genes
expressed in granulocyte monocyte progenitors as compared
with normal pre-B cells (Elane, Prtn3, and Ctsg) (www.immgen.
org/index_content.html) were upregulated in Ph+ B cells lacking
g-catenin (Table S1), suggesting that g-catenin suppresses a
myeloid gene expression program in BCR-ABL1+ B cells. How-
ever, the analysis of myeloid cell-surfacemarkers or Mpo protein
did so far not provide evidence for enhanced myeloid differenti-
ation of Jup/ Ph+ B cells (data not shown).
We next focused on the expression of Wnt pathway compo-
nents and targets (http://www.stanford.edu/group/nusselab/
cgi-bin/wnt/). Based on our gene array and qPCR, we identified
several Wnt responsive/pathway genes whose expression was
significantly decreased (Myc, Tcf7L1 [Tcf3], Grb10), increased
(Axin2, CD44, Lgr5) or unaltered (Tcf7 [Tcf1], Lef1) in Jup/
Ph+ B cells (Figure 4A and Table S1). Thus, g-catenin exerted
diverse effects on the expression of a subset of known Wnt
responsive/pathway genes.
We focused on thewell-knownWnt targetMyc, whose expres-
sion was reduced in BCR-ABL1+ Jup/ B cells based on array
and qPCR analysis (2-fold, p <0.03) (Figure 4B). Compared(I) WT recipients (CD45.1) transplanted with BCR-ABL1 (p185) (GFP) transduc
beginning 7 days later and analyzed for survival. Data are from one experiment w
(J) LSK cells from Myc+/+ andMycD/+ mice were analyzed for MYC expression us
(K) Survival of WT recipients (CD45.1) transplanted with BCR-ABL1 (p210) transd
(L) MYC expression in ex vivo isolated BCR-ABL1+ (p210) Myc+/+ and MycD/+ LS
All bar graphs and the scatterplot (G) show means ± SD. *p < 0.05, **p < 0.01, p
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sion or rather, BCR-ABL1 prevented the downregulation ofMyc,
which was observed when immature B cells differentiated past
the B220+BP-1+CD43+/ immunoglobulin M (IgM) stage (Fig-
ure 4B), i.e. the passage of the pre-B cell receptor checkpoint.
Thus, BCR-ABL1 sustained Myc expression and this was
reduced approximately 50% in the absence of g-catenin. In
the absence of b-catenin, Myc expression was not altered
(Figure 4C).
We hypothesized that the 2-fold reduction in Myc expression
was critical for B-ALL initiation or maintenance. To mimic this
situation, we exploited Myc heterozygous mice (Myclox/+ 3
Vav-Cre termed MycD/+) (Figure S5A). Deletion of a single Myc
allele indeed reducedMycmRNA in pre-B cells by approximately
50% (Figure 4D) but had no significant effect on B cell develop-
ment (Figure S5B). Transduction ofMyc+/+ control BMwith BCR-
ABL1 (p210) mediated B-ALL disease in 100% of recipient mice
(13/13; 100%). In contrast, a single recipient ofMycD/+ BMdevel-
oped B-ALL disease (1/13, 8%) and most recipients remained
disease free for >60 days post transplantation (Figures 4E and
4F). Thus, a reduced Myc gene dosage prevents B-ALL
induction.
WhileMyc+/+ andMycD/+ BM cells were transduced with com-
parable efficiencies (data not shown), there were fewer pre-
leukemic MycD/+ B cells (Figure 4G) and these expressed >50%
less Myc mRNA compared with corresponding Myc+/+ cells
(Figure 4H). While BCR-ABL1+ MycD/+ B cells eventually van-
ished, non-transduced (mCherry) MycD/+ LSK cells (CD45.2+)
remained present and these contributed long-term to all hemato-
poietic lineages includingBcells (FigureS5Canddatanot shown).
Unlike B-ALL initiation, normal B cell development was thus not
Myc dosage sensitive. We further addressed whether the contin-
uous presence of both Myc alleles was needed to maintain Ph+
B-ALL. To this end, we transduced Myclox/+ Mx1-Cre BM with
BCR-ABL1 (p185) before transplantation into recipient mice.
Seven days post transplantation, deletion of one Myc allele was
induced by pIC treatment. The majority of pIC-treated animals
survived >60 days while untreated recipients succumbed to
B-ALL disease between days 40 and 45 post transplantation (Fig-
ure 4I). Recipients ofMyclox/+ BM (lackingMx1-Cre) succumbed
toB-ALL independent of pIC treatment (Figure4I). Thus, themain-
tenance of Ph+ B-ALL depends on the continuous presence of
bothMyc alleles.
WhileMyc is required forCML initiation,we addressedwhether
CML initiation wasMyc gene dosage dependent. Comparedwith
Myc+/+, MycD/+ LSK cells indeed expressed around 50% less
Myc mRNA or protein (Figure 4J). Following transduction with
BCR-ABL1 and transplantation, Myc+/+ and MycD/+ LSK cells
yielded CML with equivalent efficiency (Figure 4K) in agreement
with Reavie et al. (2013). PCR analyses ensured that MycD/+
CML were indeed devoid of one Myc allele (Figure S5D), and
flow cytometry showed that BCR-ABL1+ MycD/+ LSK cellsed Myclox/+ and Myclox/+ Mx1-Cre BM cells (CD45.2) were injected with pIC
ith n = 5–7 mice per group.
ing qRT-PCR and flow cytometry. Numbers indicate the MFI of MYC staining.
uced Myc+/+ and MycD/+ LSK cells.
K cells.
< 0.001. ns, not significant (p > 0.05). See also Figure S5 and Table S1.
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Figure 5. MYC Is an Essential g-Catenin Target in Ph+ B-ALL
(A) Survival of WT recipients (CD45.1) transplanted with MYC (RFP) and/or BCR-ABL1 (p185) (GFP) transduced Juplox/lox Mx1-Cre BM cells (CD45.2) and treated
with pIC (beginning on day 7). Data are from two independent experiments with n = 9–10 per group, except n = 4 mice for the MYC-only group.
(B) PCR analyses to confirm Jup deletion in sorted B-ALL cells of the indicated type.
(C) BCR-ABL1 (GFP) andMYC (RFP) expression by CD45.2+ B220+ cells from the indicated type of diseased recipients or from symptom-free recipients that were
sacrificed >50 days after transplantation (i.e., recipients of BCR-ABL1/pIC or MYC BM).
(D) Schematic representation of Tcf/Lef-binding element sites (TBE) in the promoter (P1 and P2) and in 50 and 30 enhancer (Enh) elements of the humanMYC locus.
(E–G) ChIP for g-catenin (E), LEF1 (F), and b-catenin (G) using Sup-B15 chromatin followed by qPCR for indicated TBE in theMYC or in the control AXIN2 locus.
Bars depict mean fold enrichment relative to a control (ctrl) region in the same locus and relative to IgG isotype control ChIP. Data are compiled from three
independent determinations.
(legend continued on next page)
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expressed around 50% less MYC protein than WT (Figure 4L).
Unlike B-ALL, CML initiation was thus not Myc gene dosage
sensitive. The selective role of g-catenin in B-ALL can thus be
explained by the 50% reduction of MYC expression in the
absence of g-catenin.
MYC Is an Essential and Direct g-Catenin Target in Ph+
B-ALL
To address whether MYC was an essential g-catenin target, we
determined whether ectopic MYCmaintained murine Ph+ B-ALL
when Jup was deleted. BM cells from Juplox/lox Mx1-Cre mice
were transduced with MYC (RFP+) and/or BCR-ABL1 (p185)
(GFP+) before transplantation into recipient mice. Seven days
later, when the recipient’s BM harbored a population of GFP+
B220+ B cells (data not shown), Jup was deleted via pIC treat-
ment. Recipients of BCR-ABL1 BM succumbed to B-ALL when
left untreated, but survived for >50 days when treated with pIC
(Figure 5A) as also shown in Figure 2D. Conversely, recipients
of BCR-ABL1 and MYC BM all succumbed to B-ALL despite
pIC treatment (Figure 5A). PCR analyses confirmed that the
Jup locus had been deleted (Figure 5B) and flow cytometry
showed that BCR-ABL1 and MYC were co-expressed (Fig-
ure 5C). Of note, recipients of BM only transduced with MYC
remained healthy (Figure 5A) and B cells expressing ectopic
MYC were only observed when co-expressing BCR-ABL1 (Fig-
ure 5C). Thus, MYC expression was sufficient to maintain murine
Ph+ B-ALL in the absence of g-catenin.
We next used chromatin immunoprecipitation (ChIP) to deter-
mine whether g-catenin occupied Tcf/Lef consensus-binding
elements in the MYC locus of human Ph+ cell lines (Figure 5D).
Significant g-catenin occupancy was detected at 50 as well as
30 MYC enhancer elements but not at the MYC promoter or the
control AXIN2 locus (Figures 5E, S6A, and S6B). Furthermore,
LEF1was also bound to the 50 and the 30 MYC enhancer elements
aswell as to theMYCpromoter and theAXIN2 locus (Figure 5F). In
contrast, b-catenin occupied the AXIN2 locus and was not asso-
ciated with the MYC locus (Figure 5G). Indeed, knockdown of
b-catenin did not alter MYC expression in Ph+ cell lines (Fig-
ure S6C). Thus,MYC was a direct g-catenin target in Ph+ cells.
Knockdown of g-catenin in human Ph+ cells reduced MYC
expression (Figures 3D, S4A, and 5H), increased the expression
of the MYC target p21 (CDKN1A) (Figure S6D), and decreased
cellular survival and expansion (Figures 3E, 3F, S4A, 5I, and
5J). The latter effects were reproduced byMYC knockdown (Fig-
ure S6E). Ectopic MYC improved the survival and restored
cellular expansion when g-catenin knockdown was moderate
using Sh JUP1, but not when g-catenin knockdown was more
complete using Sh JUP2 (Figures 5I and 5J). The expression of
g-catenin constructs, which were resistant to Sh JUP1 or Sh
JUP2, rescued cellular expansion (Figure 7D and data not
shown), demonstrating that g-catenin was the essential target
of both Sh constructs. Thus, additional g-catenin targets
seemed to contribute to the survival of human Ph+ cells.(H–J) Human Ph+ cells (Sup-B15) stably expressing GFP (control) or MYC were tra
expression (normalized mean fluorescence intensity [MFI] of n = 3 independent e
dead cells compared with the corresponding Sh scr control [n = 8, from four indep
point, representative of >5 experiments) (J).
Error bars in (E) to (J) represent SD. ***p < 0.01. ns, not significant (p > 0.05). See
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Screening Ph+ cells for g-catenin-dependent pro-survival factors
uncovered reduced BIRC5 (Survivin) expression upon g-catenin
knockdown (Figure 6A), in agreementwithNiuet al. (2013).g-Cat-
enin reportedly associates with and promotes the activity of the
BIRC5 promoter (Kim et al., 2011), and BIRC5 knockdown
reduced the viability of a Ph+ B-ALL cell line (Tyner et al., 2012).
The relevance of BIRC5 as g-catenin target was addressed by
ectopic BIRC5 expression. Ectopic BIRC5 restored the expan-
sion of Ph+ cells using either Sh JUP1 or Sh JUP2 for g-catenin
knockdown (Figure 6B). These data thus identified BIRC5 as an
additional functionally relevant g-catenin target in human Ph+
cells. BIRC5 is also regulated by MYC in Ph+ cells (Fang et al.,
2009) and its promoter was bound by MYC (Figure S6F). Indeed,
ectopic MYC was sufficient to restore BIRC5 expression upon
g-catenin knockdown using Sh JUP1 (Figure 6C). Thus, BIRC5
was also an MYC target and consequently both an indirect as
well as a direct g-catenin target.
We extended the above analyses to murine Ph+ B-ALL.
Compared with WT B-ALL, BIRC5 expression was reduced
when g-catenin was deleted. Conversely, BIRC5 was increased
when WT B-ALL expressed MYC (Figure 6D), indicating that
BIRC5 was also regulated by g-catenin and MYC in murine
Ph+ B-ALL. To address the relevance of BIRC5, we ectopically
expressed human BIRC5 in primary murine B-ALL followed by
Jup deletion in vivo, as shown above (Figures 2D and 5A). Recip-
ients of BCR-ABL1 or BCR-ABL1 and BIRC5 BM all succumbed
to B-ALL disease (Figure 6E). When mice were treated with pIC
to delete Jup a single recipient of BCR-ABL1 BM developed
B-ALL (1/10), in agreement with Figures 2D and 5A. In contrast,
most recipients of BCR-ABL1 and BIRC5 BM succumbed to
B-ALL despite pIC treatment (Figure 6E). We confirmed that
these latter B-ALL had a deleted Jup locus (Figure 6F) and ex-
pressed the transduced BIRC5 (Figure 6G). Of note, recipients
of BM only transduced with BIRC5 remained disease free
(>60 days) (Figure 6E). Thus, ectopic BIRC5 was sufficient to
maintain Ph+ B-ALL in vivo following g-catenin ablation, indi-
cating that also BIRC5 was a functionally relevant g-catenin
target in Ph+ B-ALL.
Tyrosine Residues in g-Catenin Are Essential for Ph+
Cell Expansion and g-Catenin Recruitment to the
MYC Locus
Finally we addressed how BCR-ABL1 regulated g-catenin to
maintain B-ALL. Compared with the normal stage of B cell devel-
opment, BCR-ABL1 expression did not affect Jup mRNA
expression (Figure 7A), indicating that g-catenin was not regu-
lated by transcriptional mechanisms. In CML, BCR-ABL1 stabi-
lizes b-catenin through tyrosine phosphorylation (Coluccia et al.,
2007). In contrast, g-catenin protein amounts did not differ
between murine B cell colonies induced by interleukin-7 (IL-7)
or BCR-ABL1 (Figure S7A) or when transfecting g-catenin with
or without BCR-ABL1 into 293T cells (Figure S7B), indicatingnsduced with Sh scr, Sh JUP1, and Sh JUP2 constructs and analyzed for MYC
xperiments) (H), the abundance of apoptotic cells (change in the percentage of
endent experiments]) (I), and cellular expansion (n = 3 determinations per time
also Figure S6.
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Figure 6. BIRC5 Is an Essential g-Catenin Target in B-ALL
(A and B) Ph+ cells (K562) expressing GFP (control), MYC or BIRC5 were stably transduced with control Sh scr, Sh JUP1, or Sh JUP2 constructs and analyzed for
BIRC5 expression (normalized MFI of staining, >6 determinations) (A) and cellular expansion (n = 3 determinations per time point, representative of n = 3
independent experiments) (B).
(C) BIRC5 expression (normalized MFI) in MYC-expressing human Ph+ cells following g-catenin knockdown form n = 6–11 determinations.
(D) BIRC5 expression (normalized MFI) in primary murine B-ALL samples. n = 4 determinations derived from three independent samples.
(E) Survival of WT recipients (CD45.1) that were transplanted with BIRC5 and/or BCR-ABL1 (p185) (Cherry) transduced Juplox/lox Mx1-Cre BM cells (CD45.2) and
treated with pIC or PBS (beginning on day 7). Data are from n = 9–10 mice per group compiled from two independent experiments.
(F) PCR analyses to confirm Jup deletion in sorted CD45.2+ B220+ B-ALL cells of the indicated type.
(G) qRT-PCR analysis to confirm BIRC5 expression in BIRC5 transduced B-ALL cells.
Error bars in (A) to (D) and (G) represent SD. *p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant (p > 0.05).that BCR-ABL1 did not stabilize g-catenin protein. Notwith-
standing, g-catenin was tyrosine phosphorylated upon co-trans-
fection with kinase-active, but not with kinase-dead BCR-ABL1
in 293T cells (Figure S7B), and endogenous (data not shown)
and stably transfected g-catenin was tyrosine phosphorylated
in Sup-B15 cells (Figure 7B). We addressed the regulation of
g-catenin tyrosine phosphorylation using small-molecule inhibi-
tors (Rix et al., 2007). The ABL and SRC family kinase inhibitor
dasatinib reduced g-catenin tyrosine phosphorylation and
induced apoptosis of Sup-B15 cells, while imatinib (which in-
hibits ABL and a few receptor tyrosine kinases) or the ABL inhib-
itor nilotinib had no effect (Figures 7B and 7C). The combination
of nilotinib with the SRC inhibitor SU6656, but not SU6656 alone,
suppressed g-catenin tyrosine phosphorylation (Figure 7B) andinduced apoptosis (Figure 7C). The latter was similarly observed
in SD-1 and NALM-1 cells (data not shown). Survival of Ph+ cells
and g-catenin phosphorylation thus depended on the combined
action of BCR-ABL1 and SRC family kinases.
We next addressed whether tyrosines (Y) in g-catenin that can
be phosphorylated by SRC family kinases (Miravet et al., 2003)
played a role in Ph+ B-ALL maintenance. To this end Y133,
Y550, and Y644 of g-catenin were mutated to phenylalanine (F).
The triple Y133F, Y550F, Y644F mutant g-catenin (g-cat Mut)
and WT g-catenin (g-cat WT) constructs were further rendered
resistant to Sh JUP1 by introducing silent point mutations before
stable expression in Sup-B15 cells. Following knockdown of
endogenous g-catenin, the WT g-catenin construct rescued
cellular expansion while the triple mutant essentially failed toCancer Cell 35, 649–663, April 15, 2019 659
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Figure 7. Tyrosine Residues in g-Catenin Are
Essential for Ph+ Cell Expansion, MYC
Expression, and g-Catenin Recruitment to
the MYC Locus
(A) Expression of Jup and Lef1 during B cell devel-
opmental and in pre-leukemic Ph+ B cell samples.
(B) Sup-B15 cells expressing HA-SBP-tagged
g-catenin were treated with imatinib, nilotinib (ABL
inhibitor), dasatinib, or SU6656. g-Catenin pull-
down was analyzed for tyrosine phosphorylation.
(C) Sup-B15 cells were treated with the indicated
inhibitors and apoptosis was analyzed after 24 h
using flow cytometry for annexin versus 7-AAD.
(D–F) Sup-B15 cells were transduced with mCherry
(control), MYC-tagged WT g-catenin (g-cat WT), or
a g-catenin construct in which tyrosine (Y) 133, 550,
and 644 were changed to phenylalanine (F) (g-cat
Mut). In addition, silent mutations were introduced
to render the constructs resistant to Sh JUP1.
Following knockdown of endogenous g-catenin, we
determined cellular expansion (D), expression of the
g-catenin constructs (E), and expression ofMYC (F).
(G) Expression of HA-SBP-tagged g-cat WT and
g-cat Mut in Sup-B15 cells.
(H) ChIP for HA followed by qPCR for the TBE in the
50 and 30 enhancers of the MYC locus or for TBE2
present in the AXIN2 locus. Data are mean fold
enrichment relative to input of triplicate de-
terminations, representative of two independent
experiments.
Error bars in (A), (D), and (H) represent SD.
See also Figure S7.do so (Figure 7D). The WT and the mutant constructs were ex-
pressed at similar levels (Figure 7E), which further indicated
that these tyrosine residues did not contribute to g-catenin pro-
tein stabilization. Rather, deficient rescue by the mutant g-cate-
nin was associated with reduced MYC expression (Figure 7F).
This was accounted for by the absence of the mutant g-catenin
from the MYC 50 and 30 enhancers (Figures 7G and 7H). Thus,
the Y133, Y550, and Y644 residues are critical for the recruitment
of g-catenin to the MYC locus and for high MYC expression,
which was critical for the maintenance of Ph+ B-ALL.
DISCUSSION
Here we report an essential and selective role of g-catenin for
the progression of BCR-ABL1-induced B-ALL but not CML.660 Cancer Cell 35, 649–663, April 15, 2019Conversely, b-catenin played no essential
role in B-ALL progression but has previ-
ously been shown to be essential for
CML (Hu et al., 2009; Zhao et al., 2007).
These data identified unanticipated, non-
redundant roles of g-catenin and b-catenin
for the emergence of lymphoid and
myeloid leukemia, respectively. The key
role of g-catenin in B-ALL progression
was explained by a reduced expression
of Myc and Birc5 together with a critical
dependence of B-ALL on a normal Myc
gene dosage.It has been unclear whether g-catenin plays significant roles in
tumorigenesis and, if so, whether g-catenin functions in the
context of the canonicalWnt pathway. In solid tumors, g-catenin
loss correlates with tumor progression, development of metas-
tasis, and poor clinical outcome (Aktary and Pasdar, 2012). Loss
of g-catenin is thought to enhance b-catenin signaling due to
reduced competition for Lef/Tcf binding. Thus g-catenin is
thought to act as a tumor suppressor in solid cancers. On the
other hand, g-catenin is highly expressed in circulating tumor
cell clusters and holds these clusters together (Aceto et al.,
2014). Here it is possible that metastatic spread depends on
the adhesive role of g-catenin. Based on mouse models, human
cell lines, and patient-derived samples, our data provided
evidence that g-catenin acted as a non-oncogene addiction
gene in Ph+ B-ALL. In addition g-catenin may also play a role
in Ph-negative B-ALL. Indeed JUP is upregulated in clinical
B-ALL samples independent of t(9;22) translocation as well as
in AML. However, mutations in g-catenin are rare (42 out of
7,426 samples, www.sanger.ac.uk/genetics/CGP/) and these
are not associated with tumors of hematopoietic origin, indi-
cating that g-catenin is not an oncogene in hematological
malignancies.
A key role for the signaling function of g-catenin was sup-
ported by the finding that g-catenin expression in Ph+ B-ALL
sustained the expression of BIRC5 and MYC, which were previ-
ously identified as prominent Wnt/b-catenin/Tcf4 targets in colo-
rectal cancer (He et al., 1998; Kim et al., 2003). In B-ALL, key
MYC enhancer elements were directly associated with Lef1
and g-catenin, but not b-catenin, and g-catenin significantly
contributed to MYC expression. Direct binding of g-catenin to
the MYC promoter has previously been described in AML cell
lines (Muller-Tidow et al., 2004) and in primary keratinocytes
(Williamson et al., 2006). In the latter instance, however, g-cate-
nin binding was associated with Myc repression and cell-cycle
arrest (Williamson et al., 2006). Interestingly, the Tcf/Lef site
present in the 50 MYC enhancer, which is 300 kb away from
the promoter, affects colon cancer progression, and an SNP
within this element influences the binding of Tcf4 and b-catenin
(Tuupanen et al., 2009). It will thus be interesting to determine
whether this SNP influences g-catenin/Lef1 binding and the
predisposition to B-ALL.
Our data suggested that B-ALL initiation and maintenance
critically depended on theMyc gene dosage, while CML initiation
was more resistant to reduced MYC expression, as shown here-
in and by others (Reavie et al., 2013). Since the deletion of g-cat-
enin reducedMyc expression by approximately 50%, these data
explained the selective requirement of g-catenin for B-ALL.
Indeed, Myc expression was not significantly reduced in the
absence of b-catenin, which further underlined the distinct
behavior of Ph+ B-ALL and CML and thus the lineage-selective
roles of the two Wnt pathway intermediates.
B-ALL can be suppressed by the ABL and SRC family kinase
inhibitor dasatinib but not with single ABL kinase inhibitors (Hu
et al., 2006; Rix et al., 2007). Indeed, initiation of B-ALL de-
pends on the activity of SRC family kinases (Hu et al., 2004)
and these contribute to the resistance of B-ALL to single
ABL kinase inhibition (Hu et al., 2006; Rix et al., 2007). Along
the same line, the function of g-catenin was controlled by
the simultaneous action of ABL, and SRC family kinases and
tyrosine residues in g-catenin, which can be phosphorylated
by SRC kinases (Miravet et al., 2003), were essential for
B-ALL expansion. Indeed, B-ALL cell lines that are resistant
to single ABL kinase inhibition were susceptible to g-catenin
ablation.
Targeting the canonical Wnt pathway has significant potential
to improve the treatment of several types of leukemia. However,
Wnt signaling is also critical for the renewal of the intestinal lining,
the skin, and the hematopoietic system. Thus, blocking the Wnt/
b-catenin pathway will likely have serious side effects. The role
of g-catenin as a key factor for B-ALL progression now raises
the possibility to target a disease-specific component of the
pathway. This may considerably reduce potential side effects
and increase the therapeutic window for the treatment of B-ALL
using selective inhibitors.STAR+METHODS
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GAGCGAATA
this paper
h. MYC TBE3&4 CHIP-qPCR Reverse primer: TCGGGTGTTGT
AAGTTCCAGTG
this paper
h. MYC TBE5 CHIP-qPCR Forward primer: GGCGCTCTTAAA
CAGCTCAGTC
this paper
h. MYC TBE5 CHIP-qPCR Reverse primer: CAGACTAACACC
TTCCCGATTCC
this paper
h. MYC 5’ enhancer CHIP-qPCR Forward primer: GAGGGACGA
ATAAACTCTCCTCCT
this paper
h. MYC 5’ enhancer CHIP-qPCR Reverse primer: TCAGTGCC
TTTCATCTGCTGAG
this paper
h. MYC 5’ upstream control CHIP-qPCR Forward primer: CCTT
CACCTCATCTCTTGACAGG
this paper
h. MYC 5’ upstream control CHIP-qPCR Reverse primer: AAAG
CAACTGGACGTGGTGAA
this paper
h. AXIN2 TBE2 CHIP-qPCR Forward primer: GCTTTGATAAGG
TCCTGGCAAC
this paper
h. AXIN2 TBE2 CHIP-qPCR Reverse primer: CCGAAATCCATC
GCTCTGA
this paper
h. AXIN2 TBE3 CHIP-qPCR Forward primer: CGCCTTTGAAGT
GCACAGTTA
this paper
h. AXIN2 TBE3 CHIP-qPCR Reverse primer: AGGTCCTGTTTC
CAGCAGTCAC
this paper
h. AXIN2 5’ upstream control CHIP-qPCR Forward primer:
AGGCTAGAGAGAGGGCTTTCCA
this paper
h. AXIN2 5’ upstream control CHIP-qPCR Reverse primer:
AACAGGTGCTCGGGTCACTTTA
this paper
Recombinant DNA
Plasmid: MSCV-BCR-ABL1 (p210)-IRES-GFP X. Jiang, Terry Fox Laboratory
Plasmid: MSCV-BCR-ABL1 (p210)-IRES-mCherry this paper
Plasmid: MSCV-BCR-ABL1 (p185)-IRES-GFP O. Hantschl, EPFL
Plasmid: MSCV-IRES-GFP J. Huelsken, EPFL
Plasmid: MSCV-MYC-IRES-GFP (Hemann et al., 2005), S. Lowe RRID: Addgene_18770
Plasmid: MSCV-pBabeMCS-IRES-RFP M. Roussel and C. Sherr RRID: Addgene_33337
Plasmid: MSCV-MYC-IRES-RFP (Kawauchi et al., 2012), M. Roussel RRID: Addgene_35395
Plasmid: pLKO Sh JUP (human) (Sh JUP1) Open Biosystems TRCN0000083709
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Plasmid: pLKO Sh JUP (human) (Sh JUP2) Open Biosystems TRCN0000083710
Plasmid: pLKO Sh b-catenin (human) Open Biosystems TRCN0000003843
Plasmid: pLKO Sh b-catenin (human) Open Biosystems TRCN0000003845
Plasmid: pLKO Sh MYC (human) Open Biosystems TRCN0000174055
Plasmid: pLKO Sh MYC (human) Open Biosystems TRCN0000010390
Plasmid: pLKO Sh scrambled (Sh scr) Sigma SHC002
Plasmid: pCL Eco (Retrovirus production) Imgenex Cat# 10045P
Plasmid: pCL Ampho (Retrovirus production) B. Reina, Strasbourg
Plasmid: pCMVR8.74 (Lentivirus production) D. Trono, EPFL RRID: Addgene_22036
Plasmid: pMD2.G (Lentivirus production) D. Trono, EPFL RRID: Addgene_12259
Plasmid: Lenti pgk-BIRC5-T2A-GFP this paper
Plasmid: MSCV BIRC5 IRES-RFP this paper
Plasmid: Lenti MYC-g-catenin (human) this paper
Plasmid: Lenti MYC-g-catenin resistant to Sh JUP1
(TRCN0000083709)
this paper
Plasmid: Lenti MYC-g-catenin resistant to Sh JUP2
(TRCN0000083710)
this paper
Plasmid: Lenti MYC-g-catenin mut (Y133/550/644F) this paper
Plasmid: Lenti MYC-g-catenin mut (Y133/550/644F) resistant to
Sh JUP1 (TRCN0000083709)
this paper
Plasmid: Lenti mPgk SBP-HA-g-catenin hPgk GFP this paper
Plasmid: Lenti mPgk SBP-HA-g-catenin mut hPgk GFP this paper
Plasmid: Lenti hU6 Sh JUP1 hPgk RFP this study
Plasmid: Lenti hU6 Sh JUP1 hPgk Cerulean this study
Plasmid: Lenti hU6 Sh JUP2 hPgk RFP this study
Plasmid: Lenti hU6 Sh JUP2 hPgk Cerulean this study
Plasmid: Lenti hU6 Sh scr hPgk RFP this study
Plasmid: Lenti hU6 Sh scr hPgk Cerulean this study
Software and Algorithms
GraphPad Prism http://graphpad-prism.software.
informer.com/5.0/,
RRID: SCR_002798
FlowJo Tree Star RRID: SCR_008520
Fiji https://github.com/fiji/fiji RRID: SCR_002285
Adobe Photoshop Adobe http://www.adobe.com/
legal/terms.html
LightCycler data analysis software, Version 3.5 Roche
GeneGO MetaCore analysis software http://www.genego.com/
metacore.php
RRID: SCR_008125
ImageJ RRID: SCR_003070CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Werner
Held (Werner.Held@unil.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal experiments were conducted in accordance with protocols approved by the veterinary authorities of the Canton de Vaud and
the Kanton Zurich, Switzerland. Mouse strains were maintained in the SPF animal facilities of the University of Lausanne or the
University of Zurich. Donor and irradiated recipients of bone marrow cells were sex matched. Recipients were >6 weeks of age.Cancer Cell 35, 649–663.e1–e10, April 15, 2019 e6
Animal experiments were conducted in accordance with protocols approved by the veterinary authorities of the Canton de Vaud and
the Canton of Zurich, Switzerland.
The studies involving human subjects were approved by the ethics commission of the Kanton Zurich (approval number 2014-0383)
and informed consent was obtained from all subjects in accordance with the Declaration of Helsinki. Primary human ALL cells were
from cryopreserved bone marrow aspirates from patients enrolled in the ALL-BFM 2000 study.
METHOD DETAILS
Mouse Strains
Jup+/- (Ruiz et al., 1996), Juplox/lox (Li et al., 2011), Ctnnb1lox/lox (Huelsken et al., 2001), Myclox (Trumpp et al., 2001), Lef1+/- (van
Genderen et al., 1994), Tcf7-/- (Verbeek et al., 1995) have been described. Vav-Cre, Mx1-Cre transgenic, CD45.1 congenic
C57BL/6 (B6) and NOD Prkdcscid Il2rg-/- (NSG) mice were obtained from the Jackson Lab (Bar Harbor, ME)
Fetal Liver Chimeras
Fetal liver cells from intercrosses of Jup+/- or Lef1+/-mice (CD45.2) were obtained at day 13.5 and of day 14-16 of gestation, respec-
tively. Following genotyping by PCR appropriate fetal liver cells were injected into irradiated (900rad) B6 recipients (CD45.1). Recip-
ients were allowed to engraft for 6 to 8 weeks before further use. Hematopoietic cells in recipient mice were largely donor-derived
(>95% CD45.2+) use.
Constructs, Viral Vectors, Virus Production and Stable Transfectants
Constructs: MSCV-BCR-ABL1 (p210)-IRES-GFP (X. Jiang, Terry Fox Laboratory), MSCV-BCR-ABL1 (p210)-IRES-mCherry, MSCV-
BCR-ABL1 (p185)-IRES-GFP (O. Hantschl, EPFL), MSCV-IRES-GFP, MSCV-MYC-IRES-GFP (a gift from Scott Lowe (Addgene
plasmid # 18770), pMSCV-pBabeMCS-IRES-RFP (gift from Martine Roussel & Charles Sherr (Addgene plasmid # 33337)), MSCV-
MYC-IRES-RFP (a gift from Martine Roussel (Addgene plasmid # 35395), Lentivirus-pgk-BIRC5-T2A-GFP (codon optimized
BIRC5 synthesized by Cyagen, this paper), MSCV-BIRC5 IRES-RFP vector (this paper). Lenti based knockdown constructs (listed
in the Key Resources Table) were purchased form Open Biosystems or Sigma.
Point mutations that change tyrosines (Y) at position 133, 550 and 644 to phenylalanine (F) and/or three point mutations that render
g-catenin resistant to Sh JUP1 (available upon request) were introduced into a MYC-tagged g-catenin cDNA. Point mutations that
render g-catenin resistant to Sh JUP 2 (available upon request) were introduced into a MYC-tagged g-catenin cDNA. A streptavidin-
Binding Peptide (SBP) and three copies of the HA tag were added to the N-terminus of g-catenin. All constructs were introduced into
lentivirus vector with a bidirectional a muPgk promoter driving GFP and g-catenin.
Virus production: For the production of retroviruses, 293T cells were transiently transfected with mouse stem cell virus (MSCV)
vectors plus pCL Eco or pCL Ampho packaging plasmids. For the production of lentiviruses, 293T cells were transiently transfected
with second or third generation packaging plasmids. After concentration of culture supernatants using filter columns (Millipore), virus
supernatants were either used directly or stored frozen. Infected cells were flow sorted based on GFP or RFP fluorescence to obtain
stably transduced Ph+ cell variants.
Murine Ph+ Leukemia
Ph+ B-ALL was induced according to (Roumiantsev et al., 2001). Total BM cells (CD45.2+) were cultured in RPMI (Invitrogen), 10%
FCS, 10mMHEPES, 10 ng/ml IL-7 (R&D Systems), 10%WEHI-3B supernatant (containing IL-3), 5 mg/ml polybrene and concentrated
supernatant containing MSCV BCR-ABL1 (p210) or (p185) IRES GFP or mCherry. After 1 hr the cells were washed and 106 cells were
injected i.v. into irradiated C57BL/6 (B6) (CD45.1) recipients. To analyze B-ALL initiation from B lineage committed cells, B220+
CD19+ IgM- cells were flow sorted after the 1 hr infection and 5x105 B cells (CD45.2) were injected into irradiated WT recipient
mice (CD45.1) together with WT rescue BM cells (2.5x105) (CD45.1).
Deletion of Jupwas induced by 3 injections of polyinosinic-polycytodylic acid (poly(I:C) (pIC)) (250mg/dose) (Invivogen) on day 7, 9,
and 11 post transplantation of transduced BM.
CML-like disease using enriched HSC was induced according to (Reavie et al., 2013). Lineage marker negative (Lin-) cells were
purified from BM using the mouse hematopoietic progenitor cell isolation kit (Stemcell Technology). Lin- Sca-1+ c-Kit+ (LSK) cells
were flow sorted, pre-stimulated overnight in Opti-MEM 10%FCS, 10mMHEPES, mSCF (100 ng/ml) and TPO (20 ng/ml) (Peprotech)
and infected with MSCV BCR-ABL1 (p210) IRES GFP for 4 hr. The infection was repeated the next day and one day later 4x104 cells
(CD45.2) were injected into irradiated WT recipient mice (CD45.1) together with WT rescue BM (2.5x105) (CD45.1).
Flow Cytometry
BM and spleen cell suspensions were treated with ACK buffer to remove erythrocytes and incubated with 2.4G2 (anti-CD16/32)
hybridoma supernatant to block Fc receptors. mAbs used for multi-color flow cytometry are listed in the Key Resources Table.
Abs were conjugated to appropriate fluorochromes (FITC, PE, PE-Texas red, PE-Cy5, PE-Cy5.5, PerCP-Cy5.5, PE-Cy7,
APC, Alexa647, Alexa700, APC-Cy7, APC-Alexa780, Pacific blue, efluor450 or Pacific orange) in house or were purchased frome7 Cancer Cell 35, 649–663.e1–e10, April 15, 2019
eBiosciences, Becton Dickinson (BD) or Biolegend. 7AAD (eBiosciences), DAPI (Molecular Probes), Sytox blue (Molecular Probes) or
Aqua dead (Invitrogen) were used to gate out dead cells. Cocktail of PE-Cy7- or AF700-conjugated anti-CD3e (17A2), CD4 (GK1.5),
CD8a (53.6.7), CD11b (MI/70), CD19 (eBio1D3), B220 (RA3-6B2), GR-1 (RB6-8C5), Ter119 (Ter11)) mAbs were used to gate out
lineage-positive cells.
For cell proliferation assays, mice were injected with 100ml BrdU (BrdU flow kit, BD), and sacrificed 1 hr later. The staining was
performed according to manufacturer’s instructions. For the analysis of cell death, BM cells and splenocytes were incubated for
2 hr at 37C in RPMI plus 10% FCS in the absence of growth factors, before cell surface and AnnexinV-Cy-5 (BD) staining. Sytox
blue (Molecular Probes) was added to identify dead cells.
For MYC and BIRC5 (Survivin) detection, human Ph+ cells were fixed with 80% and 100% methanol, respectively, and resus-
pended in PBS 0.1% Tween. Goat serum was used to prevent non-specific binding before incubation with rabbit anti-MYC
(Ab32072, Abcam) or rabbit anti-human BIRC5 (Ab76424, Abcam). For p21 staining cells were fixed using the Foxp3/Transcription
Factor Staining Buffer kit (eBioscience) and incubated with rabbit anti-human p21 (2947S, Cell signaling). For BIRC5 detection in
murine Ph+ tumor samples, frozen splenocytes were thawed and Live dead dye- CD45.2+ CD45.1- B220+ cells were flow sorted.
Sorted cells were fixed with 100% methanol or using the Foxp3/Transcription Factor Staining Buffer kit (ebioscience) and then
stained using rabbit anti-mouse BIRC5 (Survivin) (2808T, Cell signaling). For MYC detection in murine LSK cells, BM cells were
enriched in hematopoietic progenitors using the mouse hematopoietic progenitor cell isolation kit (StemCell technology, 19856)
following provider’s protocol. LSK cells were flow sorted, fixed with 80% methanol, resuspended in PBS 0.1%Tween, blocked
using goat serum and stained using rabbit anti-MYC (Ab32072, Abcam). Bound primary rabbit antibodies were detected using
PE-conjugated anti-rabbit antibody (12-4739, eBioscience) and DAPI was added to exclude sub G0/G1 cells.
Samples were run on FACScanto or LSRII flow cytometers (BD), and data were analyzed using the FlowJo software package. For
cell sorting the indicated cell types were stained as described above and sorted using a FACSAria (BD) cell sorter. The purity was
generally >99% upon reanalysis.
PCR
Analysis of genomic DNA analysis was performed using Hot Start Kapa Mouse genotyping Kit (Kapa Biosystem) using the primers
listed in the Key Resources Table.
For RTqPCR, total cellular RNAwas purified using TRizol reagent (Invitrogen) and reverse-transcribed using random hexamers and
Superscript III first strand kit (Invitrogen). Real-time PCR was performed using the LightCycler FastStart DNA Master SYBR Green I
(Roche) according to the instruction manual. Primers are listed in the Key Resources Table. Transcript levels were normalized to that
of TATA-binding protein (TBP) or Hypoxanthine-guanine phosphoribosyltransferase (HPRT). Amplification plots were analyzed using
the comparative CT method with LightCycler data analysis software, Version 3.5 (Roche).
Affymetrix Microarray
Total RNAwas isolated from four sets flowsorted Jup-sufficient and Jup-deficient pre-leukemicBcells (CD45.2+CD45.1-GFP+ (BCR-
ABL1+) B220+ BP-1+) (3 weeks post transplantation) using Trizol (Gibco) and RNeasy (Qiagen) purification following manufacturer’s
instructions. cDNA was synthesized, amplified and samples were hybridized to Affymetrix GeneChip Mouse Gene 1.0 ST array.
RNA quality was checked with a Bioanalyzer (Agilent) and cDNA was synthetized. Results were analyzed using a linear model,
paired analysis. The data were preprocessed with RMA (Robust Multichip Average) normalization. Moderated t-test was used for
comparison of the 2 groupswith a p value adjustment according to Benjamini-Hochbergmethod. Technical replicates were averaged
for fold-change study. Probe sets with adjusted p value (=FDR, False Discovery Rate) <0.05 were exported to Microsoft Excel and
analyzed further using GeneGOMetaCore analysis software. The accession number for the array data reported in this paper is GEO:
GSE54793.
Colony Formation
Total BM cells were infected with BCR-ABL1 (p185) before plating in methylcellulose medium (MethoCult M3234, StemCell Technol-
ogies) in the absence of growth factor addition (2.5x104/dish). After 8 days colonies were counted, cells were harvested and replated
(104 /dish) to assess secondary colony formation and eventually tertiary colony formation.
Cell Culture and Inhibitor Treatment
For characteristics of the cell lines used please see below. K562, BV-173, TOM-1, NALM-1 (DSMZ, Germany) and SD-1 (A. Ochsen-
bein, University of Bern) were cultured in RPMI supplemented with 10% FCS, 1%PS and 10mMHEPES. Sup-B15 (DSMZ, Germany)
cells were grown in IMDM (Invitrogen) supplemented with 15% FCS, 1% PS and 10mM HEPES.
To inhibit tyrosine phosphorylation: Sup-B15 cells expressing HA-SBP-tagged g-catenin were treated for 6 hr with Imatinib (inhibits
ABL kinases and a few receptor tyrosine kinases, 10mM), Nilotinib (selectively more potent for ABL, 1mM), Dasatinib (Inhibits ABL and
SRC family kinases, 100nM) or SU6656 (potent SRC inhibitor with no activity against ABL, 1mM). g-catenin was pulled down using
Strep-Tactin and analyzed for tyrosine phosphorylation. To measure cell death: Ph+ cell lines were treated with Imatinib (1mM),Cancer Cell 35, 649–663.e1–e10, April 15, 2019 e8
Nilotinib (100nM), Dasatinib (100nM) and SU6656 (1mM). Apoptosis was analyzed after 12 hr or 24 hr using flow cytometry for Annexin
versus 7-AAD.BCR-ABL1-Positive and Negative Human Cell Lines
Cell Line Stagea Translocation mut/WT IKZF1a,b CDKN2A/Bc PAX5d IC50 Imatinib (nM)
a IC50 Dasatinib (nM)
a
NALM-1 B BC BCR-ABL1; p210;
WTa
D/WT
IK6-
D >10000 >1000
SD-1 B Lymp BCR-ABL1; p190;
WTa
IK6- >10000 n.d.
Sup-B15 pre-B BCR-ABL1; p190;
WTa
D3–6/WT
IK6+
D WT 2000 100
BV-173 B BC BCR-ABL1; p210; n.d.a IK6+ D WT 100 100
TOM-1 pre-B BCR-ABL1; p190; n.d.a D3–7/WT IK6- 80 n.d.
K562 M BC BCR-ABL1; p210; n.d.a D WT 200 n.d.
REH pre-B ETV6-RUNX1 WT
Sem pre-B MLL-AF4
697 pre-B TCF3(E2A)/PBX1 WT
B BC, B cell blast crisis; B Lymph, B lymphoblastoid; M BC, Myeloid blast crisis; mut, mutated; WT, wild-type; n.d., not determined; D, deletion, IK6:
expression of the dominant-negative Ikaros (IKZF1) splice variant 6.
a(Quentmeier et al., 2011).
b(Mullighan et al., 2008).
c(Feldhahn et al., 2007).
dhttp://cancer.sanger.ac.uk/cell_lines/gene/overview?ln=PAX5.shRNA Assays
Cells were infectedwith lentivirus based vectors (pLKO) containing specific hairpins to human g-catenin (TRCN0000083709 (Sh JUP1)
and 83710 (Sh JUP2)), human b-catenin (TRCN0000003843 and 3845) (Open Biosystems) and human MYC (TRCN0000174055 and
10390) or a scrambled sequence (Sh scr) as a negative control (SHC002, Sigma). Forty-eight hr post infection, the cells were selected
in puromycin. Three days later, puromycin resistant cells were re-plated and live cells were counted every two days and analyzed by
Western blot and cell cycle/apoptosis analysis was done using Hoechst staining.
Sup-B15 cells were transduced with sh RNA constructs (Sh JUP2 or Sh scr) and puromycin-resistant cells were transplanted (i.v.)
into sub-lethally (375 cGy) irradiated NOD Prkdcscid Il2rg-/- (NSG) mice (2*106/mouse). Two weeks later mice were sacrificed and the
presence of human cells was assessed by flow cytometry for human b2 microglobulin (b2m) relative to mouse CD45.
Primary Human Ph+ B-ALL Samples
All primary ALL samples were derived from leftover diagnostic samples from patients that were enrolled in multicenter trials on treat-
ment of pediatric ALL conducted by individual member groups of the AIEOP-BFM study group (Austria, Germany, Italy and
Switzerland). All treatment trials were approved by the respective national institutional review boards, and informed consent for
the use of spare specimens for research was obtained from study individuals, parents or legal guardians. Approval for experiments
with human samples in the mouse xenograft model to study disease mechanisms was obtained from the ethics commission of the
Canton Zurich (approval number 2014-0383). Animal experiments were approved by the veterinary office of the Canton of Zurich,
Switzerland.
To obtain xenografts, primary ALL cells were recovered from cryopreserved samples and transplanted intrafemorally to NSGmice
as previously described (Schmitz et al., 2011). Leukemia progression was monitored by flow cytometry with rat anti-mouse CD45
(eFluor450, clone 30-F11, REF 48-451-82, eBioscience), mouse anti-human CD45 (Alexa Flour 647, clone HI30, REF 304018,
BioLegend), and mouse anti-human CD19 (PE, clone HIB19, REF 302208, BioLegend). ALL cells recovered from spleens of NSG
mice were used for experiments.
Thawed patient derived Ph+ B-ALL cells were cultured overnight in Opti-MEM supplemented with 10% FCS, 10mM HEPES, 1%
penicillin-streptomycin, 10 ng/ml of IL-7 and 10% of WEHI-3B supernatant (5x106 cells/ml).
For g-catenin knockdown, we subcloned the above used hairpins to human g-catenin Sh JUP1 (TRCN0000083710) and Sh JUP2
(TRCN0000083711) and the scrambled sequence (Sh scr, SHC002) together with the hU6 promoter from the pLKO into Lentivirus
backbones containing hPGK-GFP or -Cerulean followed by a WPRE element.
After overnight pre-stimulation, the patient derived Ph+ B-ALL cells were infected with fresh concentrated supernatant containing
Sh JUP or Sh scr Lentivirus in the presence of polybrene (5 mg/ml) for 4 hr and the infection was repeated the next day. After the
second infection, the two populations of transduced cells were mixed 1:1 and injected into NSG recipient (106 cells/mouse). A small
fraction of cells was kept in culture for 2-6 days to determine the rate of transduction by flow cytometry.e9 Cancer Cell 35, 649–663.e1–e10, April 15, 2019
Characteristics of B-ALL Patient Samples
Mouse no. Sample ID BFM ID Risk Karyotype Treatment Response Relapse
Patient#1 m3292 B73 MR BCR-ABL, hyperdiploid Prednisone Good Response CNS relapse
Patient#2 m3293 ZH04 SR BCR-ABL Prednisone Good ResponsePull Down and Western Blots
Cells were lysed RIPA buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 1%NP-40) containing Phospho Stop and Protease Inhibitor
Cocktail (Roche) for 30 min at 4C. The cleared protein extract was incubated with Strep-Tactin Sepharose beads (IBA) for
15 min at 4C. Beads were washed 3x in lysis buffer and proteins were eluted for 15 min at 4C using lysis buffer containing
50mM Biotin (Sigma). Supernatants were analyzed by Westerns blots.
For Western blots, cells were lysed in Laemmli buffer (BioRad) and lysates were boiled for 10 min before running on 10% acryl-
amide gels (BioRad). After transfer to nitrocellulose (Bio-Rad), membranes were saturated using TBS with 5% milk or 0.5% gelatin
for 1 hr and incubated with primary antibodies overnight followed by appropriate secondary antibodies coupled to HRP (Horseradish
peroxidase) (see Key Resources Table) for 45 min and developed using standard ECL (GE Healthcare) or Femto ECL (Thermo
Scientific). Signals were visualized using X-Ray films (Fuji) and quantified using ImageJ software (NIH).
Chromatin Immunoprecipitation (ChIP)
Sup-B15 and K562 cells were crosslinked using a two-step method. In brief, nuclei were extracted, lysed in 10mM Tris pH8, 0.3%
SDS, 1mM EDTA, 0.5mM EGTA and sonicated to 500bp average length using a Covaris S2 sonicator. The sonicated cell lysate was
clarified by centrifugation, diluted 8x in IP buffer (10mM Tris pH8, 160mMNaCl, 1mM EDTA, 1%NP-40, 0.1% sodium deoxycholate)
and incubated with anti-g-catenin (BD 610253), anti-b-catenin (Santa Cruz sc-7199) or control rabbit IgG (Millipore 12-370) anti-
bodies pre-coupled to magnetic beads (Lifetechnologies 10001D, 10003D) over night. Complexes were washed in low (150mM
NaCl, 20mM Tris pH8, 1% sodium deoxycholate, 1% NP-40, 1mM EDTA) and high (500mM NaCl, 20mM Tris pH8, 1% sodium de-
oxycholate, 1% NP-40, 1mM EDTA) salt buffers, eluted in 25mM Tris, 10mM EDTA, 1% SDS for 30 minutes and de-crosslinked at
65C for 7 hr. Following proteinase K and RNAse treatment, DNA was purified using the Qiagen MinElute PCR purification kit. The
relative amount of immunoprecipitated DNA fragments was quantified by qPCR on input and IP samples and enrichment calculated
by normalizing with IgG control values and dividing by enrichment at control loci located upstream of either MYC or AXIN2. Five
conserved Tcf/Lef-binding elements at the MYC locus (He et al., 1998; Kolly et al., 2007; Yochum et al., 2008) were amplified as
well as a Tcf/Lef binding element of an upstream enhancer that interacts with theMYC promoter (Pomerantz et al., 2009; Tuupanen
et al., 2009). At the AXIN2 promoter two Tcf/Lef binding elements were amplified (Jho et al., 2002).
ChIP for HA tag: Sup-B15 cells were cross-linked in 1% formaldehyde (Thermo scientific, Ref: 28908), at 37C for 10 min. The re-
action was quenched with 125mM glycine, followed by 2 washes in ice-cold PBS (supplemented with protease/phosphatase inhib-
itors (1x PIC)). Fresh or frozen cell pellets were re-suspended in ChIP-lysis buffer (0.3% SDS, 50 mM Tris (pH 8.1), 10 mM EDTA
(pH 8.1), 1x PIC) and chromatin was sonicated to an average length of 200-500bp using a sonicator (Branson Sonifer 250). The son-
icated cell lysate was clarified by centrifugation, diluted 9x in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
16.7 mM Tris-HCl (pH 8.1), 167 mMNaCl, 1xPIC) and 20x106 cell equivalents of chromatin was pre-cleared with BSA-coated Protein
A+Gmagnetic beads (Millipore 16-663) for 4 hr at 40C, and then incubated overnight with anti-HA antibody (ab9110) coupled Protein
A+G magnetic beads or beads alone.
Immune complexes were in washed once each in low (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM
NaCl, 1x PIC) and high (0.1%SDS, 1%Triton X-100, 2mMEDTA, 20mMTris-HCl, pH 8.1, 500mMNaCl, 1X PIC), and LiCl salt buffers
(0.25MLiCl, 1% IGEPALCA630, 1%deoxycholic acid (sodium salt), 1mMEDTA, 10mMTris, pH 8.1, 1X PIC), and twice in Tris-EDTA
(10 mM Tris-HCl, pH 8.0, 1 mMEDTA), prior to two elutions in 1%SDS, 0.1M NaHCO3 for 30 min at 65
C, and de-crosslinked at 65C
overnight. Following proteinase K treatment at 55C for 2 hr, DNA was purified by phenol-chloroform extraction and ethanol precip-
itation. The relative amount of immunoprecipitated DNA fragments was quantified by qPCR on input and IP samples using primers
listed in the Key Resources Table and enrichment was calculated by normalizing to beads alone control values.
Data Analyses
Comparisons between two groups were performed using Student’s t tests (two tailed) and between multiple groups by ANOVA
(Bonferroni post-hoc). A Mantel-Cox test with 95% confidence interval was used to compare survival curves. Significant differences
between data sets are indicated by * p < 0.05, ** p < 0.01, *** p < 0.001. ns not significantly different (p>0.05).
DATA AND SOFTWARE AVAILABILITY
The accession number for the array data reported in this paper is GEO: GSE54793.Cancer Cell 35, 649–663.e1–e10, April 15, 2019 e10
